U.S. Electrical Stock News

Dime Community Bancshares (DCOM) Q1 2026 results in focus Dime Community Bancshares (DCOM) has just reported its Q1 2026 results with recent quarterly revenue most recently at about US$112.9 million in Q4 2025, basic EPS at US$0.67 and trailing twelve month EPS at US$2.36, set against a very large 373.9% reported earnings growth over the past year. Over the last six reported quarters, revenue has ranged from US$43.5 million in Q4 2024 to US$112.9 million in Q4 2025, while quarterly EPS has...

ARMOUR Residential REIT (ARR) opened its latest earnings season update with investors focused on how its recent results line up with a year of shifting quarterly EPS and revenue, including Q4 2025 revenue of about US$225.7 million and EPS of US$1.86. Over the past six reported quarters, revenue has ranged from a loss of US$61.3 million in Q2 2025 to US$225.7 million in Q4 2025, while EPS has swung between a loss of US$0.94 and a gain of US$1.86. This sets up this quarter’s release as a check...

Wondering whether COMPASS Pathways at around US$9.15 still stacks up on value or has run ahead of itself? This article breaks down what the recent moves might mean for you as an investor. The stock has recently shown strong momentum, with returns of 37.4% over 7 days, 75.3% over 30 days, 39.7% year to date and 129.3% over 1 year, while the 3 year return sits at 13.2% and the 5 year return at a loss of 76.5%. These swings have come as COMPASS Pathways continues to sit in the spotlight of...

If you are wondering whether Ardelyx at around US$5.96 is priced attractively or not, the key question is how that tag compares with what the business might reasonably be worth. The stock has been volatile recently, with a 5.1% decline over the last 7 days, an 11.4% gain over 30 days, a 3.1% decline year to date, and an 18.7% return over the past year, which may signal changing views on its potential and risk. Recent headlines around Ardelyx have focused on its place in the biotech space and...

If you are wondering whether ESAB at around US$102.92 is offering value or risk at this point, the recent mix of returns gives a useful starting point. Over the past week and month, the stock has returned 4.0% and 7.8% respectively, while year to date it is down 8.6%. The 1 year return shows a 13.9% decline, compared with an 80.7% gain over 3 years. Recent coverage has focused on ESAB's share price performance over different time frames and how that compares with the wider Machinery...

The United States market has remained flat over the past week but has experienced a significant 30% increase over the past year, with earnings projected to grow by 16% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for sustained revenue expansion and innovation in a dynamic economic environment.

The United States market has remained flat over the past week, yet it has experienced a notable 30% rise over the last year, with earnings projected to grow by 16% annually in the coming years. In this context, identifying stocks that are potentially undervalued can offer investors opportunities to acquire shares at a discount relative to their intrinsic value.

In the last week, the market has been flat, but over the past 12 months, it has risen by 30%, with earnings expected to grow by 16% annually in the coming years. In this context, identifying stocks with strong financial health is crucial for investors looking to capitalize on growth opportunities. Although the term "penny stocks" might seem outdated, these shares often represent smaller or newer companies that can offer significant value and growth potential when backed by solid fundamentals.

Wondering if Core & Main at around US$48.95 is offering good value right now, or if the best part of the move is already behind it. The share price shows mixed recent returns, with a 7 day move of 5.8% decline, a 30 day return of 3.2% decline, year to date at 8.4% decline, but a 3 year gain of 87.8% that may still catch your eye. Recent coverage has focused on Core & Main's position in trade distribution and how investors are reassessing companies in this niche after shifts in market...

Range Resources (NYSE:RRC) reported a record-setting first quarter of 2026, with operational and financial results ahead of prior levels. The company posted its highest-ever natural gas and NGL premiums, alongside robust free cash flow and lower debt. Range Resources authorized a new $1.5 billion share repurchase program, expanding its shareholder return plan. Range Resources enters this update with its shares at $42.64 and a strong multi-year track record, including a 20.8% gain year to...

Pegasystems (NasdaqGS:PEGA) reported a weaker-than-expected Q1 2026, with revenue and profit declining year on year. The company cited macroeconomic pressures, geopolitical tensions, and shifting client behaviors as key headwinds. Pega Cloud and AI-driven Blueprint solutions continued to gain traction, even as overall results softened. Management is emphasizing new customer acquisition and cloud adoption, with an outlook for 2026 that is more heavily weighted toward the latter part of the...

If you are wondering whether Clean Harbors at around US$310 per share is still reasonably priced, the starting point is to understand how its current market value lines up with the underlying business. The stock has posted returns of 4.6% over the last 7 days, 8.8% over the past month, 27.5% year to date, 46.4% over 1 year, 115.1% over 3 years and 245.2% over 5 years. This naturally raises questions about how expectations and risk are being priced in today. Recent headlines have focused on...

Why Amicus Therapeutics is on investors’ radar today Amicus Therapeutics (FOLD) has caught investor attention after recent performance data showed modest positive returns over the past month and past 3 months, prompting closer focus on how its rare disease portfolio supports the current valuation. See our latest analysis for Amicus Therapeutics. At a share price of $14.46, Amicus Therapeutics shows only modest short term share price returns. The 1 year total shareholder return of 100.83%...

If you are wondering whether Annaly Capital Management's share price still reflects fair value after a strong run, this article walks through what the current numbers may be saying about the stock. The stock last closed at US$22.43, with returns of 1.3% over 7 days, 6.4% over 30 days, a 2.1% decline year to date, 35.7% over 1 year, 70.0% over 3 years and 21.4% over 5 years. Recent coverage has focused on Annaly Capital Management's position within the mortgage REIT space and how interest...

Western Alliance Bancorporation (NYSE:WAL) addressed two significant fraud-related loan charge-offs in Q1 2026, which management believes helps clear legacy credit risk. The bank reported $5.6b in Q1 deposit growth and plans to shift from aggressive deposit gathering to a more balanced growth approach. These moves are intended to refine Western Alliance's risk management and funding profile following a period of strong deposit inflows. Western Alliance Bancorporation enters this shift with...

Investors may be wondering whether Cytokinetics at around US$65.48 is still offering value, or if most of the upside is already reflected in the price. The stock has returned 0.1% over the last week, 9.1% over the past 30 days, 6.1% year to date and 62.4% over the last year, with longer term returns of 73.0% over 3 years and 148.1% over 5 years. Recent coverage has focused on Cytokinetics as a biotech name that investors are watching closely, with attention on how its pipeline and...

Corpay Cross-Border, part of NYSE:CPAY, has entered a new partnership with Toulouse Football Club as the club's Official FX Supplier. The agreement extends Corpay's reach in European football, following its previously announced relationship with AC Milan. The deal focuses on supporting Toulouse FC's international payment and currency risk management needs. For readers tracking NYSE:CPAY, this Toulouse FC partnership adds another high profile sports relationship to Corpay's cross border...

Immunome plans to present full Phase 3 RINGSIDE trial data for varegacestat in desmoid tumor patients at the 2026 ASCO Annual Meeting. The company expects to file a New Drug Application with the FDA for varegacestat after the ASCO presentation. The update highlights progress toward a potential new treatment option for this rare soft tissue tumor. For investors tracking Immunome, ticker NasdaqCM:IMNM, this update centers on a late stage program that could influence the company’s future...

If you are wondering whether Molson Coors Beverage is attractively priced at around US$42.87, the key is understanding what you are getting for that share price today. The stock has been under pressure over longer periods, with a 23.6% decline over the last year and a 9.6% drop year to date, although it has risen 4.2% over the past month while slipping 2.9% in the last week. Recent news flow around Molson Coors has focused on its position in the beverage sector and how investors are weighing...

Betterware de México, S.A.P.I. de C.V. reported past first-quarter 2026 results with sales of MX$3,509.7 million, slightly above the prior year’s MX$3,499.15 million, and net income of MX$281.34 million versus MX$151.39 million. The sharp improvement in profit despite broadly flat revenue suggests the company has recently become more efficient in converting sales into earnings. Next, we’ll examine how this stronger profitability trend could influence Betterware de México’s investment...

The United States market has remained flat over the past week but has seen an impressive 30% rise over the past year, with earnings projected to grow by 16% annually. In this context, identifying stocks that are perceived as undervalued can be particularly appealing, especially when there is insider buying which may suggest confidence in their potential.

If you are wondering whether CMS Energy at around US$76.62 is priced attractively or asking too much for its future prospects, you are in the right place. The stock has seen a 1.9% decline over the last 7 days, a 1.7% return over the past month, and sits on 8.8% year to date and 6.5% over the last year. These figures will shape how you think about both upside potential and risk. Over the past three years CMS Energy has delivered a 34.9% return, and over five years the return stands at 39.6%...

The market has been flat over the last week, but it's up 30% over the past year, with earnings forecast to grow by 16% annually. For investors willing to explore beyond established giants, penny stocks can offer a unique blend of affordability and growth potential. Despite their vintage name, these smaller or newer companies can present compelling opportunities when backed by solid financials.

The United States market has experienced a flat trajectory over the past week, yet it has achieved an impressive 30% increase over the past year, with earnings projected to grow by 16% annually. In this dynamic environment, identifying dividend stocks that offer consistent income and potential for growth can be a strategic approach for investors seeking stability and returns.